Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.

被引：0

作者：

Kawaguchi, Yasunori

Aikawa, Tomomi

Shimokawa, Mototsugu

Otsuka, Taiga

Shibuki, Taro

Nakazawa, Junichi

Arima, Shiho

Miwa, Keisuke

Koga, Futa

Ueda, Yujiro

Kubotsu, Yoshihito

Shimokawa, Hozumi

Takeshita, Shigeyuki

Nishikawa, Kazuo

Hosokawa, Ayumu

Oda, Hisanobu

Sakai, Tatsunori

Shirakawa, Tsuyoshi

Mizuta, Toshihiko

Mitsugi, Kenji

机构：

[1] Asakura Med Assoc Hosp, Asakura, Japan

[2] Japan Community Healthcare Org Kyushu Hosp, Kitakyushu, Fukuoka, Japan

[3] Yamaguchi Univ, Grad Sch Med, Dept Biostat, Yamaguchi, Japan

[4] Minato Med Clin, Fukuoka, Japan

[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[6] Kagoshima City Hosp, Kagoshima, Japan

[7] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[8] Kurume Univ Hosp, Kurume, Fukuoka, Japan

[9] Saga Med Ctr Koseikan, Saga, Japan

[10] Japanese Red Cross Kumamoto Hosp, Kumamoto, Japan

[11] Karatsu Red Cross Hosp, Karatsu, Japan

[12] Japanese Red Cross Nagasaki Genbaku Hosp, Nagasaki, Japan

[13] Oita Univ, Fac Med, Yufu, Japan

[14] Univ Miyazaki Hosp, Dept Clin Oncol, Miyazaki, Japan

[15] Saiseikai Kumamoto Hosp, Kumamoto, Japan

[16] Natl Hosp Org Kumamoto Med Ctr, Kumamoto, Japan

[17] Karatsu Higashimatsuura Med Assoc Ctr, Karatsu, Japan

[18] Fujikawa Hosp, Saga, Japan

[19] Sasebo Kyosai Hosp, Sasebo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

705

引用

页码：705 / 705

页数：1

共 50 条

[21] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients [J].

C Garufi ;

E Bria ;

B Vanni ;

A M R Zappalà ;

I Sperduti ;

E Terzoli .

British Journal of Cancer, 2003, 89 :1870-1875

[22] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients [J].

Garufi, C ;

Bria, E ;

Vanni, B ;

Zappalà, AMR ;

Sperduti, I ;

Terzoli, E .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1870-1875

[23] A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX) [J].

Atkins, Katelyn Mae ;

Gong, Jun ;

Tighiouart, Mourad ;

Klempner, Samuel J. ;

Tuli, Richard ;

Placencio-Hickok, Veronica ;

Hendifar, Andrew Eugene .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

[24] A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX). [J].

Hendifar, Andrew Eugene ;

Kim, Sungjin ;

Tighiouart, Mourad ;

Hautamaki, Emily ;

Kim, Haesoo ;

Ng, Camille ;

Liu, Jar-Yee ;

Scher, Kevin S. ;

Klempner, Samuel J. ;

Placencio-Hickok, Veronica ;

Gresham, Gillian ;

Gong, Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[25] Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study [J].

Nagashima, Shuhei ;

Kobayashi, Satoshi ;

Tsunoda, Shotaro ;

Yamachika, Yui ;

Tozuka, Yuichiro ;

Fukushima, Taito ;

Morimoto, Manabu ;

Ueno, Makoto ;

Furuse, Junji ;

Maeda, Shin .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) :188-194

[26] Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study [J].

Shuhei Nagashima ;

Satoshi Kobayashi ;

Shotaro Tsunoda ;

Yui Yamachika ;

Yuichiro Tozuka ;

Taito Fukushima ;

Manabu Morimoto ;

Makoto Ueno ;

Junji Furuse ;

Shin Maeda .

International Journal of Clinical Oncology, 2024, 29 :188-194

[27] Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience [J].

Yu, Hung-Yuan ;

Lee, Chun-Yang ;

Lin, Le-Gin ;

Chao, Yee ;

Li, Chung-Pin .

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (01) :42-50

[28] PROSPECTIVE TRIAL OF CETUXIMAB PLUS IRINOTECAN FOR OXALIPLATIN AND IRINOTECAN-BASED CHEMOTHERAPY-REFRACTORY PATIENTS ADVANCED AND/OR METASTATIC COLORECTAL CANCER, EVALUATION OF THE EFFICACY AND SAFETY BASED ON MUTATION STATUS OF THE EGFR RELATED GENES [J].

Shimodaira, H. ;

Soeda, H. ;

Gamoh, M. ;

Andoh, H. ;

Yamaguchi, T. ;

Watanabe, M. ;

Ishobe, H. ;

Sudo, T. ;

Kato, S. ;

Ishioka, C. .

ANNALS OF ONCOLOGY, 2012, 23 :119-119

[29] A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy [J].

Grierson, Patrick M. ;

Suresh, Rama ;

Tan, Benjamin ;

Pedersen, Katrina S. ;

Amin, Manik ;

Park, Haeseong ;

Trikalinos, Nikolaos A. ;

Liu, Jingxia ;

Boice, Nicholas ;

Brown, Amberly ;

Bansod, Sapana ;

Wang-Gillam, Andrea ;

Lim, Kian-Huat .

CLINICAL CANCER RESEARCH, 2023, 29 (23) :4733-4739

[30] Phase II Trial of Cetuxirnab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801) [J].

Soeda, Hiroshi ;

Shimodaira, Hideki ;

Gamoh, Makio ;

Ando, Hideaki ;

Isobe, Hideki ;

Suto, Takeshi ;

Takahashi, Shin ;

Kakudo, Yuichi ;

Amagai, Kenji ;

Mori, Takahiro ;

Watanabe, Mika ;

Yamaguchi, Takuhiro ;

Kato, Shunsuke ;

Ishioka, Chikashi .

ONCOLOGY, 2014, 87 (01) :7-20

← 1 2 3 4 5 →